21529, a novel adenylate cyclase
US6403358B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 5, 1999 |
| Grant date | Jun 11, 2002 |
| Priority date | — |
| Expiry date | Oct 5, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel adenylate cyclase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length adenylate cyclase proteins, the invention further provides isolated adenylate cyclase fusion proteins, antigenic peptides, and anti-adenylate cyclase antibodies. The invention also provides adenylate cyclase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an adenylate cyclase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.